Breaking News
Sort by:
Top Post
NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business
NEC Corporation and NOI announced that NOI will be realigned as a subsidiary of NEC […]
Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma
Antengene Corporation Limited (“Antengene“ SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, […]
Antengene Announces XPOVIO ® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications
Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, […]
Antengene and XtalPi Announce AI-Driven R&D Collaboration
Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, […]
Antengene Enters into a Research Collaboration & License Option Agreement with LegoChem Biosciences for New Antibody-Drug Conjugate Candidates
Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing […]
- Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis Read more
- NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business Read more
- Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions Read more
- Sensorion Appoints Khalil Barrage as Interim Chairman of the Board Read more
- Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China Read more